Drug Approval | March 01, 2024
Biocon Biologics secures US market entry date for Bmab 1200
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
The acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting antithymic stromal lymphopoietin (TSLP) monoclonal antibody
Commercialization of rPEG lipids designed to improve immunogenicity profile for nucleic acid delivery
The agreement sets terms under which POC will manufacture the product or receive royalties
Adjuvants are components of vaccines that help to enhance the magnitude, breadth, and duration of the immune response to vaccination
1,000 Ph.D. students will be enrolled in the next five years to drive innovation in the critical healthcare sector
Exblifeb demonstrates remarkable efficacy in treating complicated Urinary Tract Infections (cUTI), pneumonia
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Subscribe To Our Newsletter & Stay Updated
